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Transplantation of kidneys from donors with hepatitis C antibody into
recipients pre-transpantation anti-HCV. Hepatitis C virus (HCV) is
transmitted by organ transplantation. Consequently, several organ pro-
curement organizations have imposed a moratorium on use of organs
from anti-HCV positive donors. Because of the inadequate supply of
cadaver kidneys for transplantation, we adopted a policy to transplant
kidneys from anti-HCV donors into anti-HCV positive recipients. During
the period between March 1990 and December 1992, 24 anti-HCV
positive dialysis patients received a kidney from anti-HCV positive donors
(group I) and 40 anti-HCV positive patients received a kidney from
anti-HCV negative donors (group II). We compared the prevalence of
liver disease, anti-HCV, HCV RNA, graft and patient survival between
groups.Pre-transplantation 17 of 24 (71%) patients in group I and 31 of 40
(79%) of patients in group II had serum HCV RNA. Post-transplantation
follow-up was 26 8 months and 30 10 months in groups I and II,
respectively. During follow-up, elevated ALT levels were present in 7 of 24
(29%) and 16 of 40 (40%) of patients in groups I and II, respectively (P>
0.05). Post-transplantation, all patients in both groups retained anti-HCV.
The prevalence of HCV RNA post-transplantation was 22 of 23 (96%)
patients in group I and 30 of 39 (77%) of patients in group II (P> 0.05).
Graft and patient survival in group I (96% and 100%, respectively) were
not significantly different from those in group 11(93% and 98%, respec-
tively). The results of this study demonstrate the short-term safety of using
kidneys from anti-HCV positive donors in anti-HCV positive recipients.
However, this policy may not prevent transmission of HCV. A safer
strategy would be to transplant kidneys from anti-HCV positive donors
into recipients with HCV RNA.
Liver disease is an important cause of morbidity after renal
transplantation, and the newly cloned hepatitis C virus (HCV) is
an important cause of post-transplantation liver disease [1]. The
observation that HCV is transmitted by organ transplantation
[2—4] has led several organ procurement organizations to restrict
the use of organs from anti-HCV positive donors to life-saving
transplants such as heart, liver or lung [2—51. With the prevalence
of anti-HCV among cadaver organ donors as high as 8.3% in
some populations [6], such a policy would severely reduce the
already inadequate supply of cadaver kidneys for transplantation.
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Therefore, some authors have suggested that kidneys from anti-
HCV donors be transplanted into anti-HCV positive recipients
[7, 8].
In Spain, 630 cadaver donors were procured in 1992 [9].
Nonetheless, more than 6000 patients with chronic renal failure
on dialysis are awaiting kidney transplantation [10]. Therefore, in
March 1990, the Hospital 12 de Octubre, Madrid, and Hospital
Clinic, Barcelona adopted a policy to transplant kidneys from
anti-HCV donors into anti-HCV positive recipients, after in-
formed consent from the recipient. Three and one half years after
the implementation of this policy, we examined the safety of such
transplants. We compared the prevalence of liver disease, anti-
HCV and HCV RNA before and after transplantation in 24
anti-HCV positive recipients of kidneys from anti-HCV positive
donors and a control group of 40 anti-HCV positive recipients of
kidneys from anti-HCV negative donors.
Methods
Study Population
During the period between March 1990 and December 1992,
310 renal transplants were performed at the Hospital 12 de
Octubre, Madrid (Center I), and Hospital Clinic, Barcelona
(Center II). Sixty-four (21%) recipients were anti-HCV positive
pre-transpiantation. Twenty-four received a kidney from anti-
HCV positive donors (group I) and 40 received a kidney from
anti-HCV negative donors (group II). The study was approved by
the Departments of Nephrology and Transplantation at each
hospital. Informed consent was obtained from each patient in
group I.
Clinical Data
Pre-transpiantation. Pre-transplantation records were reviewed
(JMM in Madrid and JMC in Barcelona) for age, gender, etiology
of chronic renal failure, number of blood transfusions, duration of
dialysis, number of previous transplants, history of drug abuse,
liver disease or therapy with hepatotoxic drugs, serum alanine
aminotransferase (ALT) levels, serological tests for human immu-
nodeficiency virus (HIV), hepatitis B virus (HBsAg, anti-Hbc) and
liver histology. Pre-transplantation sera were tested for anti-HCV
and for HCV RNA. Liver biopsies were performed before trans-
plantation or in the first month after transplantation.
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Post-transplantation. The post-transplantation follow-up includ-
ed: monitoring of serum ALT levels at monthly intervals; testing
of serum for anti-HCV at 3, 6, 9, 12, 18 and 24 months; and testing
of serum for HCV RNA at the most recent follow-up. Post-
transplantation immunosuppression, incidence of acute rejection,
treatment with OKT3, cytomegalovirus infection, date and cause
of graft loss and death, and renal function at most recent
follow-up were recorded. Thirty-eight patients received steroids
(0.5 mg/kg/day) and cyclosporine (10 mg/kg/day), and the others
received cyclosporine alone (12 mg/kg/day). In patients with a
high titer of lymphocytotoxic antibodies directed against a panel
of randomly selected blood donors, primary therapy included
antithymocyte globulin (ATG, The Upjohn Company, Kalama-
zoo, MI, USA) 12 mg/kg/day or muromonab-CD3 (OKT3, Ortho
Biotech, Raritan, NJ, USA) 5 mg/kg/day for the first seven days.
Acute rejection episodes were treated with intravenous methyl-
prednisolone (1 g) for three days. Corticosteroid resistant rejec-
tions were treated with OKT3 (5 mg IV) for 10 to 14 days.
Definitions
Clinical. The presence of liver disease was based on serum
alanine aminotransferase (ALT) levels [111. A mild abnormality
was defined as increase in ALT, greater than 45 U/L but less than
2.5 times the upper limit of normal. Chronic liver disease was
defined as an ALT level greater than 2.5 times the upper limit of
normal for more than six months.
Pathological. Diagnosis of minimal changes, acute hepatitis or
chronic active hepatitis was based on standard criteria [12, 13].
Laboratory Tests for HCV
Anti-HCV. Donor and recipient sera were tested for anti-HCV
using a second generation ELISA (Ortho HCV ELISA 2.0 Test
System, Ortho Diagnostic Systems) and a second generation strip
immunoblot assay (RIBATM HCV Test System, Chiron Corpora-
tion, Emeryville, CA, USA). The second generation ELISA
(ELISA2) detected antibody to recombinant HCV antigens (clOO,
c200 and c22) from the non-structural and core regions of the
HCV genome. The second generation immunoblot assay (RIBA2),
detected antibody to antigens (5-1-1, clOO, c33, c22) from the
non-structural and core regions of the HCV genome and was used
as a supplemental test for anti-HCV [14]. Both tests were carried
out according to the manufacturers' instructions.
HCV RNA. All available donor and recipient sera were tested
for HCV RNA by polymerase chain reaction (PCR). All donor
and recipient samples from each center were tested at a single
laboratory at that center.
Methods for PCR at Center I. A nested PCR protocol was used
(Ravaggi, PCR Meth App, 1992). Briefly, 3 tL of serum were
directly added to 22 tL reverse transcriptase mix (50 mrvi TRIS
HC1 pH 8.2, 70 mivi KC1, 10 mrvi MgCl2, 4 mrvi dDT, 40 id of
human placental ribonuclease inhibitor, 0.25% nonidet P-40, 50
M of a 5 UTR specific antisense primer (1CH) and 200 LM
dNTPs in H20-DEPC). After denaturation for five minutes at
92°C, 4 d of AMV-RT were added, cDNA synthesis was carried
out at 42°C for 60 minutes. Amplification was performed follow-
ing the nested protocol [15] with two set of primers amplifying a
fragment located in the 5' non-coding region of the viral genome
generating a PCR product of 187 bp. For the demostration of the
amplified segments an enzymatic test (DEIA HCV Sorin Bio-
medica, Salugia, Italy) was used [16].
Table 1. Demographic and clinical characteristics
ELISA 2 positive recipients
ELISA2 ELISA2
positive donor negative donor
Recipient characteristics (N = 24) (N = 40)
Age years 47 12 44 14
Gender
Male 16 (67%) 24 (60%)
Female 8 (33%) 16 (40%)
Renal disease
CGN 13 (55%) 14 (35%)
CIN 7 (29%) 13 (33%)
AH 2 (8%) 3 (7%)
CD 0(0%) 2(5%)
Others 2 (8%) 8 (20%)
Pre-transplant transfusions number° 7 8 21 39
Duration of dialysis months 72 53 75 49
Previous transplant 2 (8%) 8 (20%)
History of drug abuse 0 (0%) 0 (0%)
HIV positive 0 (0%) 0 (0%)
HBsAg positive 2 (8%) 1(3%)
Anti-HBc positive 12 (50%) 9 (23%)
Numbers indicate mean SD or number (percent) of patients
Abbreviations are: M, male; F, female; CGN, chronic glomerulonephri-
tis; CIN, chronic interstitial nephritis; All, arterial hypertension; CD,
cystic disease.
"P <0.05
Methods for PCR at Center II. RNA was purified from 50 il of
serum by the method described by Garson and colleagues [15].
After reverse transcription of 2 jfl of RNA, a nested PCR was
performed using primers from the 5' non-coding region of the
HCV genome [17]. The 144 bp amplification products were
visualized on polyacrilamide gels by ethidium bromide and ultra-
violet light.
At both laboratories, strict precautions were taken to avoid
contamination [18]. Positive and negative controls were run in
parallel in all experiments.
Statistical analysis
Groups were compared with Student's t-test and the chi-square
test (with Yates correction when appropriate). We considered
differences between groups significant if the P value was less than
0.05.
Results
Pre-transpiantation
Table 1 shows the demographic and clinical characteristics prior
to transplantation in recipients of kidneys from donors with
anti-HCV (group I) and without anti-HCV (group II). With the
exception of the number of blood transfusions (7 8 in group I
and 21 39 in group II, P < 0.05) there were no significant
differences between the two groups with regard to age, gender,
renal disease, duration of dialysis, number of previous transplants,
history of drug abuse, prevalence of a positive test for HIV,
HbsAg or anti-Hbc.
Table 2 compares the prevalence of liver disease prior to
transplantation in both groups. Elevated ALT levels were present
in 13 of 24 (54%) and 20 of 40 (50%) of patients in groups I and
II, respectively. Among patients in group I, four of 13 (31%)
patients who had a liver biopsy had histological evidence of liver
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Table 2. Clinical, biochemical and histological characteristics, and
markers of hepatitis C infection before and after transplantation in
ELISA2 positive recipients of kidneys from ELISA2 positive and
negative donors
ELISA2 positive recipients
ELISA2 ELISA2
positive donor negative donor
Recipient characteristics (N = 24) (N = 40)
Pre-transplantation
Elevated ALT 13/24 (54%) 20/40 (50%)
Mild abnormalities 12 18
Chronic liver disease 1 2
Abnormal liver histology 4/13 (31%) 9/18 (50%)
Chronic persistent hepatitis 4 3
Chronic active hepatitis 0 4
Hemosiderosis 0 2
RIBA2 positive 24/24 (100%) 40/40 (100%)
PCR positive 17/24 (71%) 31/40 (79%)
Post-transplantation
Follow-up months 26 8 30 10
(range) (12—39) (9—39)
Elevated ALT 7/24 (29%) 16/40 (40%)
Mild abnormalities 5 13
Chronic liver disease 2 3
ELISA2 positive 24/24 (100%) 40/40 (100%)
RIBA2 positive 24/24 (100%) 40/40 (100%)
PCR positive 22/23 (96%) 30/39 (77%)
Graft survival 23/24 (96%) 37/40 (93%)
Patient survival 24/24 (100%) 39/40 (98%)
Abbreviations are: ELISA2, anti-HCV positive by the second genera-
tion ELISA (Ortho); RIBA2, anti-HCV positive by second generation
RIBA (Chiron); PCR, polymerase chain reaction; ALT, alanine amino-
transferase; +, positive; —, negative.
disease. All four had chronic persistent hepatitis. Among patients
in group II, nine of 18 (50%) patients who had a liver biopsy had
histological evidence of liver disease. Of these, three had chronic
persistent hepatitis, four had chronic active hepatitis and two had
hemosiderosis.
All patients in both group I and II were positive by RIBA2.
Seventeen of 24 (71%) patients in group I and 31 of 40 (79%) of
patients in group II tested positive for HCV RNA by PCR.
Post-transplantation
Table 2 also compares the outcomes of transplantation in both
groups. Post-transplantation follow-up was 26 8 months and 30
10 months in groups I and II, respectively. During follow-up,
elevated ALT levels were present in 7 of 24 (29%) and 16 of 40
(40%) of patients in group I and II, respectively (P> 0.05). All
patients in group I and II retained anti-HCV by both ELISA2 and
RIBA2. Of the patients in whom post-tranplantation sera were
available, 22 of 23 (96%) patients in group I and 30 of 39 (77%)
of patients in group tested positive for HCV RNA by PCR (P>
0.05). There were no differences in the incidence of acute
rejection, OKT3 rescue therapy or cytomegalovirus infection
between groups (data not shown). The graft and patient survival
in group I (96% and 100%, respectively) were not significantly
different from those in group 11(93% and 98%, respectively). The
causes of graft loss were obstructive uropathy in the single
recipient in group I, and chronic rejection in two recipients in
group II. One patient in group II died due to respiratory failure.
Serum creatinine levels at the most recent follow-up were similar
in groups I and II (1.7 0.4 mg/dl and 1.8 0.5 mg/dl,
respectively).
Relation of donor and recipients pre-transpiantation HCV RNA to
outcomes of transplantation
Table 3 shows the results of PCR testing in donors and
recipients in group I. Paired donor and recipient (pre- and
post-transplantation) sera were available for PCR testing in ten
anti-HCV positive donors. Eight donors tested positive for HCV
RNA and two tested negative. Kidneys from the eight HCV RNA
positive donors were transplanted into fourteen recipients, of
whom pre-transpiantation testing for HCV RNA was positive in
nine and negative in five. All nine HCV RNA positive recipients
of kidneys (100%) tested positive for HCV RNA post-transplan-
tation, and only one (11%) had mild elevation of ALT. Of the five
HCV RNA negative recipients, four (80%) tested positive for
HCV RNA after transplantation and two (40%) had chronic liver
disease after transplantation. Kidneys from the two HCV RNA
negative donors were transplanted into two recipients, both of
whom tested positive for HCV RNA pre-transplantation. Both
recipients tested positive for HCV RNA post-transplantation, and
neither had abnormal ALT levels.
Discussion
The prevalence of a positive second generation anti-HCV test
among cadaver organ donors is 4.2% and 1.6%, respectively, in
the U.S. and Spain, and varies widely among different geograph-
ical regions within the countries [6, 9]. Consequently, a morato-
rium on the use of organs from anti-HCV positive donors would
result in a loss of 190 of the 4,520 cadaver donors (up to 380
kidneys) procured in the U.S. in 1992, and 10 of the 630 cadaver
donors (up to 20 kidneys) procured in Spain in the same year [9,
19]. The high prevalence of HCV infection among chronic dialysis
patients awaiting kidney transplantation, and the existing shortage
of cadaver kidneys led us to evaluate the safety of using kidneys
from anti-HCV positive donors in anti-HCV positive dialysis patients
awaiting transplantation.
Our study shows that the prevalence of post-transplantation
liver disease, graft survival and patient survival among anti-HCV
positive recipients of kidneys from anti-HCV positive donors was
not significantly different from that of anti-HCV positive recipi-
ents of kidneys from anti-HCV negative donors. However, the
number of patients was small and the duration of follow-up was
short. Further, the morbidity and mortality from liver disease is
often manifest in the second decade after transplantation [20—22].
Hence, the power of the study to detect an adverse effect may
have been limited. Nevertheless, such transplants appear to be
safe, at least in the short-term.
The use of organs from anti-HCV positive donors in anti-HCV
positive dialysis patients awaiting transplantation is potentially
fraught with problems. First, there are several strains of HCV
[23]. Studies in post-transfusion hepatitis C in chimpanzees
demonstrated that previous infection with HCV did not protect
from reinfection with a different strain or even the same strain of
the virus [24]. In fact, repeat exposure did not protect against
reappearance of viremia, biochemical or histological evidence of
liver disease. Similar data are not available from post-transfusion
studies in humans.
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Table 3. Characteristics of ELISA2 positive recipients of kidneys from ELISA2 positive donors
ELISA2 positive
donors
PCR
ELISA2 positive recipients
Pre-transpiant Post-transplant
PCR ALT
Liver
biopsy PCR
Follow-up
months ALT
D-1 +
D-1 +
D-2 ND
D-2 ND
D-3 —
D-4 +
D-5 ND
D-5 ND
D-6 ND
D-6 ND
D-7 +
D-7 +
D-8 +
D-8 +
D-9 +
D-9 +
D-10 —
D-11 ND
D-12 +
D-13 +
D-13 +
D-14 ND
D-15 +
D-15 +
R-1
R-2
R-3
R-4
R-5
R-6
R-7
R-8
R-9
R10'
R-11
R-12
R-13
R-14
R15a
R-16
R-17
R-18
R-19
R-20
R-21
R-22
R-23
R-24
—
—
+
+
+
+
+
+
+
+
—
—
+
+
+
+
+
—
+
+
—
—
+
+
Mild abnm
Mild abnm
Mild abnm
CLD
Mild abnm
Mild abnm
Mild abnm
Mild abnm
Normal
Normal
Normal
Normal
Mild abnm
Mild abnm
Normal
Normal
Mild abnm
Normal
Normal
Mild abnm
Normal
Mild abnm
Normal
Normal
ND
ND
Normal
Normal
Normal
Normal
ND
ND
Normal
Normal
Normal
Normal
CPH
CPU
ND
ND
Normal
ND
ND
CPH
ND
CPH
ND
ND
-4-
—
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
ND
+
+
44
44
28
28
27
26
25
25
23
23
23
23
18
18
26
26
44
44
17
21
21
21
19
19
CLD
Normal
Mild abnm
Mild abnm
Normal
Mild abnm
Mild abnm
Mild abnm
Normal
Normal
CLD
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Each donor and recipient was designated by the letter D and R, respectively, and by a number. Abbreviations are: ELISA2, anti-HCV positive by the
second generation ELISA (Ortho); PCR, polymerase chain reaction; ALT, alanine aminotransferase; +, positive; —, negative; ND, not done; Mild
abnm, mild abnormality; CLD, chronic liver disease; CPH, chronic persistent hepatitis.
a HB5Ag positive
Second, the current anti-HCV tests detect non-neutralizing
antibodies to recombinant ITICV antigens, and hence a positive
test represents exposure to the virus, and not immunity. The
positive predictive value of anti-HCV tests in identifying ongoing
HCV infection in potential recipients is limited [3, 25]. Pre-
transplantation, only 71% of anti-HCV positive recipients in this
study tested positive for HCV RNA. Among the five anti-HCV
positive but PCR negative recipients of kidneys from anti-HCV
positive donors, four (80%) acquired HCV RNA after transplan-
tation, and two of the recipients developed biochemical evidence
of chronic liver disease. This may represent transmission of HCV
infection from anti-HCV positive donors to anti-HCV positive but
HCV RNA negative recipients. Hence, a safer strategy would be
to test anti-HCV positive patients on the waiting list for HCV
RNA, and allocate organs from anti-HCV positive donors only to
those recipients that test positive for HCV RNA. This strategy
would ensure maximum utilization of organs from anti-HCV
positive cadaver donors, and at the same prevent the transmission
of HCV infection to anti-HCV positive patients without HCV
RNA.
In summary, the results of this study demonstrate the short-
term safety of using kidneys from anti-HCV positive donors in
HCV RNA positive recipients. However, many questions remain
unanswered. Nonetheless, given the current shortage of cadaver
organs, we suggest a policy of transplantation of organs from
anti-HCV positive donors into HCV RNA positive recipients.
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